|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | ONE JOHNSON & JOHNSON PLAZA |
Address2 | |
City | NEW BRUNSWICK |
State | NJ |
Zip Code | 08933 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 20686-12
|
||||||||
|
6. House ID# 303480000
|
TYPE OF REPORT | 8. Year | 2008 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Clifford Holland, Corporate Vice President, Government Affairs and Policy |
Date | 01/19/2009 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
-H.R. 3043 / S 1710, "Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008," regarding appropriations;
-H.R. 3161 / S. 1859, "Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2008," regarding drug importation;
-H. Con. Res. 99, "Revising the congressional budget for the United States Government for fiscal year 2008, and setting forth appropriate budgetary levels for fiscal years 2009 though 2012," regarding healthcare funding issues.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brian |
Burns |
|
|
|
Cathy |
Dooley |
|
|
|
Darrel |
Jodrey |
|
|
|
Charles |
Nau |
|
|
|
Susan |
Reardon |
|
|
|
Caroline Moody |
Schellhas |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
-H.R. 1908 / S. 1145, "Patent Reform Act of 2007," regarding amending title 35, United States Code, to provide for patent reform;
-Thailand Compulsory License.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Nau |
|
|
|
Susan |
Reardon |
|
|
|
Mark |
Reese |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
-H.R. 1591, "U.S. Troop Readiness, Veterans' Health, and Iraq Accountability Appropriations Act, 2007," regarding Medicaid rebates; -H.R. 2585, "National Defense Authorization Act for Fiscal Year 2008," regarding TRICARE;
-H.R. 3222, "Department of Defense Appropriations Act of 2008", regarding appropriations for the Department of Defense.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jane |
Adams |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
-H.R. 1424, "Paul Wellstone Mental Health and Addiction Equity Act of 2007," regarding amending section 712 of the Employee Retirement Income Security Act of 1974, section 2705 of the Public Health Service Act, and section 9812 of the Internal Revenue Code of 1986 to require equity in the provision of mental health and substance-related disorder benefits under group health plans;
-H.R. 1494 / S. 830, "Pediatric Medical Device Safety and Improvement Act of 2007," regarding improving the process for the development of needed pediatric medical devices;
-H.R. 1956, "Patient Protection and Innovative Biologic Medicines Act of 2007," regarding amending the public Health Service Act to provide for the approval of similar biological products;
-H.R. 2193, "Animal Protection Accountability Improvement Act," regarding amending the Animal Welfare Act to increase the penalties for violations of such Act to prohibit the use of animals for marketing medical devices;
-H.R. 2349/ S. 1413, "Uterine Fibroid Research and Education Act of 2007," regarding providing for research and education with respect to uterine fibroids;
-H.R. 3333 / S. 1576, "Minority Health Improvement and Health Disparity Elimination Act," regarding amending the Public Health Services Act to improve the health and healthcare of racial and ethnic minority groups;
-H.R. 788 / S. 468, "Food and Drug Administration Safety Act of 2007," regarding amending the Federal Food, Drug, and Cosmetic Act with respect to drug safety;
-H.R. 2900, "Food and Drug Administration Amendments Act of 2007," regarding amending the Federal Food, Drug, and Cosmetic Act to revise and extend the use-fee programs for prescription drugs and for medical devices and to enhance the postmarket authorities of the Food and Drug Administration with respect to the safety of drugs;
-S. 1082, "Food and Drug Administration Revitalization Act," regarding amending the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act to reauthorize drug and device user fees and ensure the safety of medical products;
-S. 1695, "Biologics Price Competition and Innovation Act of 2007," regarding amending the Public Health Service Act to establish a pathway for the licensure of biosilimar products to promote innovation in the life sciences;
-S. 467, "Fair Access to Clinical Trials Act of 2007 or the 'FACT Act'," regarding amending the Public Health Services Act to expand clinical trials drug data bank;
-S. 558, "Mental Health Parity Act of 2007," regarding all provisions ;
-S. 628, "Critical Access to Health Information Technology Act of 2007," regarding improving grants for rural health information technology development activities;
-S. 993, "Pediatric Research Improvement Act," regarding improving pediatric research; issues regarding Acetemorphine and Phenelyperine;
-H.R. 3580, "Food and Drug Administration Amendments Act of 2007," regarding fees related to prescription drugs, medical devices, and food safety;
-H.R. 2419 / S. 2302, "Food and Energy Security Act of 2007," regarding marketing and financial assistance related to farming and food production;
-H.R. 5606 / S. 2029, "Physician Payments Sunshine Act of 2007," regarding amending Title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, or medical supplies for which payment is made under Medicare, Medicaid, or SCHIP;
-S. 2221, "Transparency in Medical Device Pricing Act of 2007," regarding amending Title XVIII of the Social Security Act to provide for the reporting of sales price data for implantable devices;
-H.R. 3043, "Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2008," regarding appropriations for the Department of Health and Human Services;
-H.R. 5629, "Pathway for Biosimilar Act," regarding amending the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products;
-H.R. 5839, "Safeguarding America's Pharmaceuticals Act of 2008", To Amend the Federal Food, Drug, and Cosmetic Act to improve the safety of drugs, regarding all provisions;
-S. 334, "Healthy Americans Act", A bill to provide affordable, guaranteed private health coverage that will make Americans healthier and can never be taken away, regarding all provisions;
-H.R. 6381, "Medical Device Safety Act of 2008", To amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices, regarding all provisions;
-S. 438, "Fair Prescription Drug Competition Act", A bill to amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs, regarding all provisions;
-S.2274, "A bill to amend the Controlled Substances Act to prevent the abuse of dextromethorphan", and for other purposes, regarding all provisions.
-S.3409 "A bill to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety and quality of medical products and enhance the authorities of the Food and Drug Administration", and for other purposes; regarding all provisions.
-S.1378 "A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan", and for other purposes; regarding all provisions.
-S. 3408, "Comparative Effectiveness Research Act of 2008", A bill to amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Comparative Effectiveness Research Trust Fund, and for other purposes, regarding all provisions;
-S. 1276, "Methamphetamine Production Prevention Act of 2008", A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to liability under State and local requirements respecting devices, regarding all provisions.
-Proposed Rule (CMS-1403-P), Regarding revisions to Amendment of the E-Prescribing Exemption for Computer Generated Facsimile Transmissions;
-S.2424, "A bill to ensure that all Americans have basic health literacy skills to function effectively as patients and health care consumers", regarding all provisions.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jane |
Adams |
|
|
|
Brian |
Burns |
|
|
|
Darrel |
Jodrey |
|
|
|
Charles |
Nau |
|
|
|
Susan |
Reardon |
|
|
|
Mark |
Reese |
|
|
|
Caroline Moody |
Schellhas |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code LAW
16. Specific lobbying issues
-S. 635, "Methamphetamine Remediation Research Act of 2007," regarding providing for a research program for remediation of closed methamphetamine production laboratories; issues regarding Federal judicial salaries;
-S. 2274, "Dextromethorphan Abuse Reduction Act of 2007", A bill to amend the Controlled Substances Act to prevent the abuse of dextromethorphan, and for other purposes, regarding all provisions;
-S. 1378, "Dextromethorphan Distribution Act of 2007", A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the distribution of the drug dextromethorphan, and for other purposes;
-S. 1276, "Methamphetamine Production Prevention Act of 2008 ", A bill to establish a grant program to facilitate the creation of methamphetamine precursor electronic logbook systems, and for other purposes, regarding all provisions.
-S.2071, "A bill to enhance the ability to combat methamphetamine", regarding all provisions.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brian |
Burns |
|
|
|
Darrel |
Jodrey |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
-H.R. 2762 / S. 1494, "To amend the Public Health Services Act to reauthorize the special diabetes program for Type 1 diabetes and Indians under the Act," regarding all provisions;
-H.R. 2349/ S. 1413 "Uterine Fibroid Research and Education Act of 2007", To provide research and education with respect to uterine fibroids, and for other purposes, regarding all provisions.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jane |
Adams |
|
|
|
Susan |
Reardon |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
-H.R. 1190, "Community Cancer Care Preservation Act of 2007," regarding amending title XVIII of the Social Security Act to preserve access to community cancer care by Medicare beneficiaries;
-Proposed Rule (CMS-1404-P), "CY 2009 Outpatient Prospective Payment System Rules".
-H.R. 1321,Medicare Advanced Laboratory Diagnostics Act of 2007, regarding amending title XVIII of the Social Security Act to improve payments under the Medicare clinical laboratory fee schedule;
-H.R. 1663, Medicare Mental Health Modernization Act of 2007, regarding amending title XVIII of the Social Security Act to expand and improve coverage of mental health services under the Medicare Program;
-H.R. 1845 / S 1428, Medicare Durable Medical Equipment Access Act of 2007, regarding amending part B of title XVIII of the Social Security Act to assure access to durable medical equipment under the Medicare Program;
-H.R. 2770, To amend title XVIII of the Social Security Act to ensure more appropriate payment amounts for drugs and biologicals under part B of the Medicare Program by excluding customary prompt pay discounts extended to wholesalers from the manufacturer's average sales price, all provisions;
-H.R. 3011, To amend title XVIII of the Social Security Act to ensure adequate payment amounts for drugs and biologicals under part B of the Medicare Program, regarding all provisions;
-H.R. 3061, Medicare Part D Drug Class Protection Act of 2007, regarding amending title XVIII of the Social Security Act to require that Medicare prescription drug plans using formularies cover all drugs included in 6 specified therapeutic categories and to establish protective requirements for coverage determinations;
-H.R. 4 / S 3, Medicare Prescription Drug Price Negotiation Act of 2007, regarding amending part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate lower covered part D drug prices on behalf of Medicare beneficiaries;
-H.R. 976 / S 1893, Children's Health Insurance Program Reauthorization Act of 2007;
-H.R. 3162, Children's Health and Medicare Protection Act of 2007, regarding improving enrollment and retention of eligible children;
-S. 1887, Medicare Access to Critical Medications Act of 2007, regarding amending title XVIII of the Social Security Act in order to ensure access to critical medications under the Medicare part D prescription drug program;
-S. 631, Remote Monitoring Access Act of 2007, regarding amending title XVIII of the Social Security Act to provide for coverage of remote patient management services for chronic health care conditions under the Medicare Program;
-S. 860, Early Treatment for HIV Act of 2007, regarding amending title XIX of the Social Security Act to permit States the option to provide Medicaid coverage for low-income individuals infected with HIV;
-CMS-1270-F, Medicare Program; Competitive Acquisition for Certain Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) and Other Issues, regarding a final rule establishing competitive bidding programs for certain Medicare Part B covered items of durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) throughout the United States in accordance with sections 1847(a) and (b) of the Social Security Act; issues regarding competitive bidding, demonstrations for clinical lab services and competitive Medicare payments for lab services; issues regarding Medicare national coverage determination for the use of erythropoiesis stimulating agents in cancer and related neoplastic conditions;
-CMS-2238-FC, regarding the Medicaid program, and prescription drugs;
-S. 2499, "Medicare, Medicaid, and SCHIP Extension Act of 2007," all provisions.
-S. 2029, "Physician Payments Sunshine Act of 2007," regarding amending title XI of the Social Security Act to provide for transparency in the relationship between physicians and manufacturers of drugs, devices, or medical supplies for which payment is made under Medicare, Medicaid or SCHIP;
-H.R. 5765 / S. 631, "Medicare Remote Monitoring Access Act of 2008," regarding amending title XVIII of the Social Security Act to cover remote patient management services for certain chronic health conditions under the Medicare Program;
-H.R. 6252, "Medicare DMEPOS Competitive Acquisition Reform Act of 2008", To amend part B of title XVIII of the Social Security Act to delay and reform the Medicare competitive acquisition program for purchase of durable medical equipment, prosthetics, orthotics, and supplies, regarding all provisions;
-S. 2404, "Medicare Advanced Laboratory Diagnostics Act of 2007", A bill to amend title XVIII of the Social Security Act to improve payments under the Medicare clinical laboratory fee schedule, regarding all provisions;
-H.R. 6331/ S. 3101, "Medicare Improvements for Patients and Providers Act of 2008", A bill to amend titles XVIII and XI of the Social Security Act to extend expiring provisions under the Medicare program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes, regarding all provisions;
-H.R. 2770, "To amend title XVIII of the Social Security Act to ensure more appropriate payment amounts for drugs and biologicals under part B of the Medicare Program by excluding customary prompt pay discounts extended to wholesalers from the manufacturer's average sales price", regarding all provisions.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jane |
Adams |
|
|
|
Brian |
Burns |
|
|
|
Cathleen |
Dooley |
|
|
|
Darrel |
Jodrey |
|
|
|
Charles |
Nau |
|
|
|
Susan |
Reardon |
|
|
|
Mark |
Reese |
|
|
|
Caroline Moody |
Schellhas |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
-H.R. 2589, "Improving Pharmaceuticals for Children Act of 2007," regarding amending the Federal Food, Drug, and Cosmetics Act and the Public Health Service Act to reauthorize and amend the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act.
-S. 1156, Best Pharmaceuticals for Children Amendments of 2007, regarding amending the Federal Food, Drug, and Cosmetic Act to reauthorize the Best Pharmaceuticals for Children program;
-S. 242, Pharmaceutical Market Access and Drug Safety Act of 2007, regarding amending the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs;
-S. 251, Pharmaceutical Market Access Act of 2007, regarding amending the Federal Food, Drug, and Cosmetic Act with respect to the importation of prescription drugs;
-H.R. 4083 / S. 2311, "Non-Prescription Drug Modernization Act of 2007," regarding amending the Federal Food, Drug, and Cosmetic Act to provide for the amendment or repeal of monographs, to expand the Food and Drug Administration's authority to regulate drug advertising, and for other purposes;
-S. 1951, "Fair Medicaid Drug Payment Act of 2007," regarding amending title XIX of the Social Security Act to ensure that individuals eligible for medical assistance under the Medicaid program continue to have access to prescription drugs, and for other purposes.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brian |
Burns |
|
|
|
Darrel |
Jodrey |
|
|
|
Charles |
Nau |
|
|
|
Mark |
Reese |
|
|
|
Caroline Moody |
Schellhas |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
-H.R. 1712, "Research and Development Tax Credit Act of 2007," regarding amending the Internal Revenue Code of 1986 to provide incentives to improve America's research competitiveness;
-H.R. 6049, "Energy Improvement and Extension Act of 2008", To amend the Internal Revenue Code of 1986 to provide incentives for energy production and conservation, to extend certain expiring provisions, to provide individual income tax relief, and for other purposes, regarding all provisions;
-H.R. 763, "To amend the Internal Revenue Code of 1986 to make permanent the deduction allowable with respect to income attributable to domestic production activities in Puerto Rico," all provisions;
-S. 41, "Research Competitiveness Act of 2007," regarding amending the Internal Revenue Code of 1986 to provide incentives to improve America's research competitiveness;
-H.R. 3970, "Tax Reduction and Reform Act of 2007," regarding general tax provisions and corporate tax reforms;
-H.R. 3359, "Mobile Workforce State Income Tax Fairness and Simplification Act of 2007," regarding limiting the authority of States and localities to tax certain income of employees for employment duties performed in other States and localities;
-H.R. 5267, "Business Activity Tax Simplification Act of 2008," regarding simplifying the business activity tax and expand the federal prohibition against state taxation of interstate commerce to include taxation of out-of-state transactions involving all forms of property, including intangible personal property and services and sets forth criteria for determining that a person has a physical presence in a state;
-S. 2209, "Research Credit Improvement Act of 2007", A bill to amend the Internal Revenue Code of 1986 to provide incentives to improve America's research competitiveness, and for other purposes, regarding all provisions;
-S. 2886, "Alternative Minimum Tax and Extenders Tax Relief Act of 2008", A bill to amend the Internal Revenue Code of 1986 to amend certain expiring provisions", regarding all provisions;
-S. 3098, "Alternative Minimum Tax and Extenders Tax Relief Act of 2008", A bill to amend the internal Revenue code of 1986 to extend certain expiring provisions, and for other purposes, regarding all provisions;
-S. 3125, "Energy Independence and Tax Relief Act of 2008", A Bill to amend the Internal Revenue Code of 1986 to extend certain expiring provisions, and for other purposes, regarding all provisions;
-H.R. 7060, "Renewable Energy and Job Creation Tax Act of 2008", To amend the Internal Revenue Code of 1986 to provide incentives for energy production and conservation, to extend certain expiring provisions, to provide individual income tax relief, and for other purposes, regarding all provisions;
-H.R. 1424, "Paul Wellstone Mental Health and Addiction Equity Act of 2007", A bill to provide authority for the Federal Government to purchase and insure certain types of troubled assets for the purposes of providing stability to and preventing disruption in the economy and financial system and protecting taxpayers, to amend the Internal Revenue Code of 1986 to provide incentives for energy production and conservation, to extend certain expiring provisions, to provide individual income tax relief, and for other purposes, regarding all provisions.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brian |
Burns |
|
|
|
Caroline Moody |
Schellhas |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
-Issues regarding bilateral free trade agreements with South Korea, Peru, Columbia, and Panama;
-S. 2731, "Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008", A bill to authorize appropriations for fiscal years 2009 through 2013 to provide assistance to foreign countries to combat HIV/AIDS, tuberculosis, and malaria, and for other purposes, regarding all provisions.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brian |
Burns |
|
|
|
Susan |
Reardon |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
-H.R. 3610, "Food and Drug Import Safety Act of 2007," regarding fees related to food safety.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brian |
Burns |
|
|
|
Darrel |
Jodrey |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENV
16. Specific lobbying issues
-S. 2191, "America's Climate Security Act of 2007", regarding a provision to direct the Administrator of the Environmental Protection Agency to establish a program to decrease emissions of greenhouse gases, and for other purposes.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Nau |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code GOV
16. Specific lobbying issues
-H.R. 3753/S. 1638, "Federal Judicial Salary Restoration Act of 2007", to adjust the salaries of Federal justices and judges, and for other purposes;
-H.R 4854/S. 2041, "False Claims Act Correction Act of 2007", to amend the provisions of title 31, United States Code, relating to false claims to clarify and make technical amendments to those provisions, and for other purposes.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brian |
Burns |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |